Literature DB >> 17577296

Health status impairment and costs associated with COPD exacerbation managed in hospital.

J F O'Reilly1, A E Williams, L Rice.   

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) have serious health consequences for patients and are strongly associated with unscheduled healthcare resource use. This study used a preference-based quality of life measure questionnaire (EQ-5D) to evaluate the impact of exacerbation on health status and utility during a patient's admission to hospital and short-term follow-up. Costs of admission were calculated. In total, 149 patients consented to take part in the study representing 222 admissions to hospital. At admission patients reported high levels of problems for all dimensions of the EQ-5D. Mean utility (-0.077) and Visual Analogue Scale (25.9) values indicated great impairment, with 61% of patients having a negative utility value representing a health state equivalent to 'worse than death' at admission. Many problems were still reported at discharge. By 3 months follow-up patients had deteriorated, with percentages of patients reporting problems in mobility (98%) and usual activity (88%) almost back up to admission levels. Health status and utility values were similar regardless of lung function at admission and at discharge. Approximately half of the patients in each category had a negative utility value at admission representing a health state 'worse than death', with similar levels of improvement by discharge. The mean cost of an admission was 2130.34 pounds (SD 1326.09) with only a mean of 110.37 pounds(5%) because of medication. No differences were noted by lung function category. In conclusion, all COPD patients requiring admission for an exacerbation suffer a serious deterioration in health status which, although improves during admission, notably deteriorates by 3 months postdischarge.

Entities:  

Mesh:

Year:  2007        PMID: 17577296     DOI: 10.1111/j.1742-1241.2007.01424.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  15 in total

Review 1.  Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.

Authors:  Maureen P M H Rutten-van Mölken; Lucas M A Goossens
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

2.  Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Martine Hoogendoorn; Leida M Lamers
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Utility estimation in chronic obstructive pulmonary disease: a preference for change?

Authors:  Jennifer Petrillo; Floortje van Nooten; Paul Jones; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

4.  Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ.

Authors:  Petra Menn; Norbert Weber; Rolf Holle
Journal:  Health Qual Life Outcomes       Date:  2010-04-15       Impact factor: 3.186

Review 5.  Optimizing chronic disease management mega-analysis: economic evaluation.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2013-09-01

Review 6.  Association between lung function and exacerbation frequency in patients with COPD.

Authors:  Martine Hoogendoorn; Talitha L Feenstra; Rudolf T Hoogenveen; Maiwenn Al; Maureen Rutten-van Mölken
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-12-09

7.  Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions.

Authors:  Mattias Neyt; Stephan Devriese; Nancy Thiry; Ann Van den Bruel
Journal:  BMC Pulm Med       Date:  2010-09-15       Impact factor: 3.317

8.  Utility estimation of hypothetical chronic obstructive pulmonary disease health states by the general population and health professionals.

Authors:  Sujin Cho; Hochang Kim; Seon-Ha Kim; Minsu Ock; Yeon-Mok Oh; Min-Woo Jo
Journal:  Health Qual Life Outcomes       Date:  2015-03-13       Impact factor: 3.186

9.  Longitudinal change in quality of life following hospitalisation for acute exacerbations of COPD.

Authors:  John Steer; G John Gibson; Stephen C Bourke
Journal:  BMJ Open Respir Res       Date:  2015-01-15

10.  Early assisted discharge with generic community nursing for chronic obstructive pulmonary disease exacerbations: results of a randomised controlled trial.

Authors:  Cecile M A Utens; Lucas M A Goossens; Frank W J M Smeenk; Maureen P M H Rutten-van Mölken; Monique van Vliet; Maria W Braken; Loes M G A van Eijsden; Onno C P van Schayck
Journal:  BMJ Open       Date:  2012-10-16       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.